natgillin/translations-raw huggingface dataset:
- Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
- Skraćenje trajanja neutropenije i smanjenje incidencije febrilne neutropenije u bolesnika koji se liječe utvrđenom citotoksičnom kemoterapijom zbog zloćudne bolesti (uz iznimku kronične mijeloične leukemije i mijelodisplastičnih sindroma) i skraćenje trajanja neutropenije u bolesnika koji primaju mijeloablativnu terapiju prije presađivanja koštane srži u kojih se smatra da postoji povećani rizik od produljenog trajanja teške neutropenije.
1 pre-filled syringe with a needle safety guard 3 pre-filled syringes with a needle safety guard 5 pre-filled syringes with a needle safety guard 10 pre-filled syringes with a needle safety guard
1 napunjena štrcaljka sa sigurnosnom zaštitom za iglu 3 napunjene štrcaljke sa sigurnosnom zaštitom za iglu 5 napunjenih štrcaljki sa sigurnosnom zaštitom za iglu 10 napunjenih štrcaljki sa sigurnosnom zaštitom za iglu
• if you get left upper belly (abdominal) pain, pain below the left rib cage or pain at the tip of your shoulder, as there may be a problem with your spleen [enlargement of the spleen (splenomegaly) or rupture of the spleen].
• ako osjetite bolove u gornjoj lijevoj strani trbuha (abdomena), bol na lijevoj strani ispod rebara ili bol u vršku ramena, jer može postojati problem sa slezenom [povećanje slezene
Discontinuation of filgrastim therapy usually results in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to normal levels in 1 to 7 days.
Prekid terapije filgrastimom obično rezultira 50 %-tnim smanjenjem cirkulirajućih neutrofila unutar 1 do 2 dana, uz vraćanje na normalne razine za
Reversal of neutropenia or maintaining normal neutrophil counts: Filgrastim should be given by subcutaneous injection.
Oporavak od neutropenije ili održavanje normalnog broja neutrofila: Filgrastim treba davati supkutanom injekcijom.
A meta-analysis of allogeneic transplant studies, including the results of nine prospective randomized trials, eight retrospective studies and one case-controlled study, did not detect an effect on the risks of acute GvHD, chronic GvHD or early treatment-related mortality.
Metaanaliza ispitivanja alogenih transplantacija, uključujući i rezultate devet prospektivnih randomiziranih ispitivanja, 8 retrospektivnih ispitivanja i 1 ispitivanje parova, nije otkrila utjecaj na rizik od akutne
Transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied.
Prolazna trombocitopenija (trombociti < 100 x 109/l) nakon primjene filgrastima i leukafereze primijećena je u 35 % ispitivanih ispitanika.
When administered for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte counts rise to > 70 x 109/l.
U slučaju primjene radi mobilizacije progenitorskih stanica iz periferne krvi, potrebno je prekinuti primjenu ili smanjiti dozu filgrastima ako se broj leukocita poveća na vrijednosti > 70 x 109/l.
During long term use cutaneous vasculitis has been reported in 2% of SCN patients.
Tijekom dugotrajne primjene kožni vaskulitis je zabilježen u 2 %
Accidental freezing will not harm Filgrastim HEXAL.
Slučajno zamrzavanje neće naškoditi lijeku Filgrastim HEXAL.
Filgrastim HEXAL is a clear, colourless to slightly yellowish solution for injection or infusion in prefilled syringe.
Filgrastim HEXAL je bistra, bezbojna do svijetložuta otopina za injekciju ili infuziju u napunjenoj štrcaljki.
In order to determine a patient's trough or nadir ANC, it is recommended that blood samples are taken for ANC measurement immediately prior to any scheduled dosing with filgrastim.
Da bi se u bolesnika odredio najniži apsolutni broj neutrofila, preporučuje se uzimati uzorke krvi za mjerenje apsolutnog broja neutrofila neposredno prije svakog planiranog doziranja filgrastima.
Solution for injection or infusion in pre-filled syringe.
Otopina za injekciju ili infuziju u napunjenoj štrcaljki.
Filgrastim HEXAL stimulates the bone marrow to produce new white cells quickly.
Filgrastim HEXAL stimulira koštanu srž da brže proizvodi nove bijele krvne stanice.
Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than 1.5 x 109/l.
Filgrastim treba svakodnevno primjenjivati supkutanom injekcijom sve dok broj neutrofila ne postane veći od 1,5 x 109/l i dok se može zadržati na toj vrijednosti.
Permanently discontinue Filgrastim HEXAL in patients with clinically significant hypersensitivity.
Trajno prekinite davanje lijeka Filgrastim HEXAL u bolesnika s klinički značajnom preosjetljivosti.
What you need to know before you use Filgrastim HEXAL Do not use Filgrastim HEXAL
Što morate znati prije nego počnete primjenjivati Filgrastim HEXAL
Filgrastim HEXAL has not been tested in pregnant or breast-feeding women.
Filgrastim HEXAL nije proučavan na trudnicama ili dojiljama.
There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim.
U kliničkim ispitivanjima je primijećena niska učestalost (približno 3 %) mijelodisplastičnih sindroma (MDS) ili leukemija u bolesnika s teškom kroničnom neutropenijom liječenih filgrastimom.
The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.
Sigurnost i djelotvornost primjene filgrastima slične su u odraslih i djece koji primaju citotoksičnu kemoterapiju.
Congenital, idiopathic or cyclic neutropenia: Filgrastim should be given by subcutaneous injection.
Način primjene Prirođena, idiopatska ili ciklička neutropenija: Filgrastim treba davati u obliku supkutane injekcije.
Filgrastim had no observed effect on the fertility of male or female rats.
Nije uočen učinak filgrastima na plodnost mužjaka ili ženki štakora.
Congenital neutropenia
Doziranje Kongenitalna neutropenija:
Cases of splenomegaly and splenic rupture have been reported following administration of filgrastim.
Zabilježeni su slučajevi splenomegalije i rupture slezene nakon primjene filgrastima.
Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient abnormal bone scans.
Pojačana hematopoetska aktivnost koštane srži kao odgovor na terapiju čimbenikom rasta povezuje se s prolaznim pozitivnim nalazima slikovnih pretraga kostiju.
There have been reports of Graft versus Host Disease (GvHD) and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.8 and 5.1).
Graft versus Host Disease - GvHD) i smrtni ishodi u bolesnika koji su primali G-CSF nakon alogene transplantacije koštane srži (vidjeti dio 4.8 i 5.1).
It is currently unclear whether long-term treatment of patients with SCN will predispose patients to cytogenetic abnormalities, MDS or leukaemic transformation.
Trenutno nije jasno predisponira li dugotrajno liječenje bolesnika s teškom kroničnom neutropenijom za citogenetske abnormalnosti, MDS ili prijelaz u leukemiju.
Rare (≥ 1/10,000 to
Manje često (≥1/1000 i
The dosage recommendations in paediatric patients are the same as those in adults receiving myelosuppressive cytotoxic chemotherapy.
Preporuke za doziranje u pedijatrijskih bolesnika iste su kao i preporuke za odrasle koji primaju mijelosupresivnu citotoksičnu kemoterapiju.
Description of selected adverse reactions
Opis odabranih nuspojava Preosjetljivost
The effects of filgrastim on neutropenia due to bone marrow-infiltrating infection or malignancy have not been well established.
Učinci filgrastima na neutropeniju zbog infekcije ili zloćudne bolesti koja infiltrira koštanu srž nisu dobro utvrđeni.
Use of filgrastim in patients, children or adults, with SCN (severe congenital, cyclic, and idiopathic neutropenia) induces a sustained increase in ANCs in peripheral blood and a reduction of infection and related events.
Primjena filgrastima u bolesnika, djece ili odraslih s teškom kroničnom neutropenijom (teška kongenitalna, ciklička i idiopatska neutropenija) dovodi do stabilno povećanog apsolutnog broja neutrofila u perifernoj krvi i smanjenja infekcija te s time povezanih događaja.
Chronic GvHD TRM
GvHD TRM
Always keeping your skin pinched, depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further.
Uvijek držite nabor kože između prstiju i potiskujte klip polako i jednolično sve dok ne primijenite dozu i klip se više ne može dalje potisnuti.
Pseudogout (chondrocalcinosis pyrophosphate)
Pseudogiht (hondrokalcinoza pirofosfat)
Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy, suggesting no age-related differences in the pharmacokinetics of filgrastim.
Podaci iz kliničkih ispitivanja pedijatrijskih bolesnika ukazuju da su sigurnost i djelotvornost filgrastima slične u odraslih i djece koji primaju citotoksičnu kemoterapiju, što upućuje na to da razlike u farmakokinetici filgrastima nisu povezane sa starošću.
Depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further.
Polako i jednolično pritišćite klip sve dok ne primijenite cijelu dozu i dok se klip ne može dalje potisnuti.
In clinical trials, 97% of patients who responded had a complete response at doses ≤ 24 μg/kg/day.
U kliničkim je ispitivanjima 97 % bolesnika s odgovorom imalo potpuni odgovor na doze
1995 - 2000b a Analysis includes studies involving BM transplant during this period; some studies used GM-CSF b Analysis includes patients receiving BM transplant during this period
Međunarodno retrospektivno ispitivanje (2006) 1995 - 2000b a Analiza uključuje ispitivanja presatka koštane srži tijekom tog razdoblja; neka su ispitivanja koristila
Hyperuricaemia Blood uric acid increased
Hiperuricemija Povišena mokraćna kiselina u krvi
In patients undergoing a stem cell or bone marrow transplant, Graft versus Host Disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.
Graft versus Host Disease - GvHD) - to je reakcija stanica davatelja na bolesnika koji prima presadak; znakovi i simptomi uključuju osip na dlanovima ili tabanima te vrijed/čir i rane u ustima, crijevu, jetri, koži ili očima, plućima, vagini i zglobovima.
Filgrastim HEXAL must not be diluted with sodium chloride solution.
Filgrastim HEXAL se ne smije razrijediti otopinama natrijevog klorida.
Dizziness may occur following the administration of filgrastim (see section 4.8).
Nakon primjene filgrastima može doći do omaglice (vidjeti dio 4.8).
In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1 - 2 days after initiation of filgrastim therapy.
Prolazno povećanje broja neutrofila u bolesnika koji primaju citotoksičnu kemoterapiju obično se uočava 1 - 2 dana nakon početka terapije filgrastimom.
• pain and swelling of the joints, similar to gout (pseudogout)
• bolovi u zglobovima i oticanje zglobova slično gihtu (pseudogiht)
* recombinant methionylated human granulocyte-colony stimulating factor (G-CSF) produced in E. coli by recombinant DNA technology.
proizveden u E. coli tehnologijom rekombinantne DNK.
Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy.
Podaci iz kliničkih studija u pedijatrijskih bolesnika sugeriraju da su sigurnost i djelotvornost filgrastima slični u odraslih i djece koja primaju citotoksičnu kemoterapiju.
• to increase the number of white blood cells after a bone marrow transplant to help prevent infections;
• za povećanje broja bijelih krvnih stanica nakon transplantacije koštane srži kako bi se spriječile infekcije;
The most commonly reported adverse reactions are pyrexia, musculoskeletal pain (which includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain), anaemia, vomiting, and nausea.
Najčešće prijavljivane nuspojave su vrućica, mišićno-koštana bol (što uključuje koštanu bol, bol u leđima, artralgiju, mijalgiju, bol u ekstremitetima, mišićno-koštanu bol, mišićno-koštanu bol u prsištu, bol u vratu), anemiju, povraćanje i mučninu.
The most serious adverse reactions that may occur during filgrastim treatment include: anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease.
Najozbiljnije nuspojave do kojih može doći tijekom terapije filgrastimom obuhvaćaju: anafilaktičku reakciju, ozbiljne plućne štetne događaje (uključujući intersticijsku bolest pluća i sindrom akutnog respiratornog distresa), sindrom povećane propusnosti kapilara, splenomegaliju/rupturu slezene, prijelaz u leukemiju ili mijelodisplastični sindrom kod bolesnika s teškom kroničnom neutropenijom,
Dilution to a final concentration < 0.2 MU/ml (2 μg/ml) is not recommended at any time.
Nikada se ne preporučuje razrjeđivanje do konačne koncentracije < 0,2 MU/ml (2 μg/ml).
Acute respiratory distress syndromea Respiratory failurea
Sindrom akutnog respiratornog distresaa
The recommended starting dose is 1.2 MU/kg/day (12 μg/kg/day) as a single dose or in divided doses.
Preporučena početna doza je 1,2 MU/kg/dan (12 μg/kg/dan) u obliku jedne ili više doza.
The first dose of filgrastim should be administered at least 24 hours following cytotoxic chemotherapy and at least 24 hours after bone marrow infusion.
Prvu dozu filgrastima treba primijeniti najmanje 24 sata nakon citotoksične kemoterapije i najmanje 24 sata nakon infuzije koštane srži.
Generally asymptomatic cases of splenomegaly and cases of splenic rupture have been reported in patients and normal donors following administration of filgrastim.
Obično asimptomatski slučajevi splenomegalije i slučajevi rupture slezene zabilježeni su u bolesnika i zdravih davatelja nakon primjene filgrastima.
Some patients may respond very rapidly and with a considerable increase in neutrophil count to the initial dose of filgrastim.
U nekih bolesnika odgovor na početnu dozu filgrastima može nastupiti vrlo brzo i uz znatno povećanje broja neutrofila.
• unusual change in the urine
• neuobičajena promjena u mokraći • smanjenje gustoće kostiju
Special care should be taken in the diagnosis of SCNs to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia, and myeloid leukaemia.
Poseban oprez potreban je kod dijagnoze teških kroničnih neutropenija kako bi ih se razlikovalo od drugih krvotvornih poremećaja, kao što su aplastična anemija, mijelodisplazija ili mijeloična leukemija.
Leukocytosis (WBC > 50 x 109/l) was observed in 41% of normal donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).
Leukocitoza Leukocitoza (leukociti > 50 x 109/l) je primijećena u 41 % normalnih davatelja, dok je prolazna trombocitopenija (trombociti < 100 x 109/l) nakon filgrastima i leukafereze primijećena u 35 %
In patients treated with myeloablative therapy followed by bone marrow transplantation
Kod bolesnika liječenih mijeloablativnom terapijom nakon koje slijedi presađivanje koštane srži
Once the neutrophil nadir has been passed, the daily dose of filgrastim should be titrated against the neutrophil response as follows:
Nakon što prođe smanjenje broja neutrofila na najnižu vrijednost, dnevna doza filgrastima treba se titrirati prema odgovoru neutrofila na sljedeći način:
Physicians should use caution when prescribing filgrastim in patients with sickle cell trait or sickle cell disease.
Liječnici trebaju s oprezom propisivati filgrastim u bolesnika s nasljednim obilježjem srpastih stanica ili s bolesti srpastih stanica.
For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation Posology
Za mobilizaciju PBPC-ova kod zdravih donora prije transplantacije alogenim PBPC-ovima
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive treatments.
Liječenje samo filgrastimom ne isključuje trombocitopeniju i anemiju zbog mijelosupresivnog liječenja.
There have been reports of GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.4 and 5.1).
Zabilježeni su slučajevi reakcija presatka protiv primatelja (GvHD) i smrtni ishodi u bolesnika koji su primali G-CSF nakon alogene transplantacije koštane srži (vidjeti dijelove 4.4 i 5.1).
The needle safety guard will cover the needle when releasing the plunger.
Sigurnosna zaštita za iglu pokrit će iglu kad otpustite klip.
Excipient with known effect Each ml of solution contains 50 mg sorbitol (E420).
Jedan ml otopine sadrži 50 mg sorbitola (E420).
Discontinue filgrastim
Prekinuti primjenu filgrastima
In patients with known bone marrow infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia.
U bolesnika u kojih se potvrdi da je infekcija ili zloćudna bolest infiltrirala koštanu srž treba razmotriti odgovarajuću terapiju za liječenje osnovne bolesti uz primjenu filgrastima zbog liječenja neutropenije.
A subset of approximately 12% of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation.
bolesnika koji su na početku imali normalne citogenetske nalaze kasnije su, na rutinski ponavljanim pregledima, otkrivene abnormalnosti, uključujući monosomiju
One retrospective European study evaluating the use of G-CSF after allogeneic bone marrow transplantation in patients with acute leukaemias suggested an increase in the risk of GvHD, treatment related mortality (TRM) and mortality when G-CSF was administered.
Jedno retrospektivno europsko ispitivanje koje je procjenjivalo primjenu G-CSF nakon alogene transplantacije koštane srži u bolesnika s akutnim leukemijama ukazalo je na povećani rizik od GvHD,
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy.
Liječenje samo filgrastimom ne isključuje pojavu trombocitopenije i anemije zbog mijelosupresivne kemoterapije.
PBPC mobilisation e Adverse events with higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy c.
e Nuspojave s povećanom učestalošću u bolesnika koji primaju filgrastim u usporedbi s placebom te povezane s posljedicama osnovne zloćudne bolesti ili citotoksične kemoterapije c.
These autologous PBPCs may be harvested and infused after high-dose cytotoxic therapy, either in place of, or in addition to bone marrow transplantation.
Ove autologne progenitorske stanice iz periferne krvi mogu se sakupiti i dati infuzijom nakon visokih doza citotoksične terapije bilo umjesto presađivanja koštane srži ili uz presađivanje koštane srži.
Kidney injury has been seen in patients who received filgrastim.
Oštećenje bubrega zna se opaziti u bolesnika koji primaju filgrastim.
Filgrastim HEXAL contains no preservative.
Filgrastim HEXAL ne sadrži konzervans.
Special precautions in patients with HIV infection
Posebne mjere opreza u bolesnika s HIV infekcijom Broj krvnih stanica
Established cytotoxic chemotherapy
Utvrđena citotoksična kemoterapija
• urinary tract infection
Infekcija urinarnog trakta
Further dose adjustment may be necessary, as determined by the patient's ANC, to maintain the neutrophil count at > 2.0 x 109/l.
Možda u bolesnika bude potrebna daljnja prilagodba doze, što se određuje prema apsolutnom broju neutrofila, da bi se broj neutrofila održao na > 2,0 x 109/l.
You will normally receive your first dose of Filgrastim HEXAL at least 24 hours after your chemotherapy and at least 24 hours after receiving your bone marrow transplant.
Uobičajeno je prvu dozu Zarzia primiti najmanje 24 sata nakon kemoterapije i najmanje 24 sata nakon transplantacije koštane srži.
• redness of the skin (erythema)
• osip • crvenilo kože (eritem)
The subcutaneous route is preferred in most cases.
U većini slučajeva prednost se daje supkutanom načinu primjene.
For maintaining normal neutrophil counts
Da bi se održao odgovarajući broj neutrofila,
Filgrastim should be diluted in 20 ml of 5% glucose solution (see section 6.6).
Filgrastim treba razrijediti u 20 ml 5-postotne otopine glukoze (vidjeti dio 6.6).
Clean the skin at the injection site using an alcohol wipe.
Tupferom natopljenim alkoholom očistite kožu na mjestu primjene injekcije.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su prikazane prema ozbiljnosti padajućim redoslijedom.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - PRE-FILLED SYRINGE WITH A NEEDLE SAFETY GUARD
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKO PAKIRANJE - NAPUNJENA ŠTRCALJKA SA SIGURNOSNOM ZAŠTITOM ZA IGLU
How to store Filgrastim HEXAL
Kako primjenjivati Filgrastim HEXAL
The recommended starting dose of filgrastim is 1.0 MU/kg/day (10 μg/kg/day).
Preporučena početna doza filgrastima je 1,0 MU/kg/dan (10 μg/kg/dan).
Leukocytosisa
Leukocitozaa
The recommended dose of filgrastim is 0.5 MU/kg/day (5 μg/kg/day).
Preporučena doza filgrastima je 0,5 MU/kg/dan (5 μg/kg/dan).
Each pre-filled syringe contains 48 million units (equivalent to 480 micrograms) filgrastim in 0.5 ml (96 MU/ml).
Jedna napunjena štrcaljka sadrži 48 milijuna jedinica (što odgovara 480 mikrograma) filgrastima u 0,5 ml (96 MU/ml).
These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4).
bolesnika koji su uzimali kemoterapiju koja se sastoji od više lijekova ili u bolesnika na aferezi (vidjeti dio 4.4).
• soreness and swelling of the digestive tract lining which runs from the mouth to the anus
• bolovi i oticanje sluznice probavnog sustava od usta do anusa (upala sluznice/mukozitis)
Astheniaa Malaisee Oedema peripherale
Astenijaa Malaksaloste Periferni edemie
4 - 5 consecutive days allows a collection of ≥ 4 x 106 CD34+ cells/kg recipient body weight in the majority of the donors after two leukaphereses.
U zdravih davatelja, doza od 1 MU/kg/dan (10 μg/kg/dan) primijenjena supkutano tijekom 4 - 5 uzastopnih dana omogućuje prikupljanje ≥ 4 x 106 CD34+ stanica/kg tjelesne težine primatelja kod većine davatelja nakon dvije leukafereze.
Infusion of PBPC accelerates haematopoietic recovery reducing the duration of risk for haemorrhagic complications and the need for platelet transfusions.
smanjujući trajanje rizika od hemoragijskih komplikacija i potrebu za transfuzijama trombocita.
• plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with a fever
• upala krvnih žila u koži (kožni vaskulitis) • tamnoplavi, uzdignuti, bolni plakovi (promjene na koži) na ekstremitetima i katkad na licu i vratu s vrućicom (Sweetov sindrom)